In the Phase II portion of the NRG-HN009 trial, weekly cisplatin did not significantly reduce acute toxicity compared with every-three-week dosing in patients with p16-negative locally advanced head and neck cancer (ID: 50e6f3fe389e5ad4). The result directly informs dosing schedule decisions when balancing toxicity, treatment burden, and feasibility. For oncology operations, the trial provides actionable comparative data rather than a purely conceptual choice between schedules. If confirmatory endpoints and full trial results align, regimens may shift toward whichever schedule supports adherence and resource constraints without worsening acute risk. The study is focused on acute toxicity rather than efficacy, so future reporting on survival and response endpoints remains key.